Index
1 Market Overview of APOL1 Mediated Kidney Disease
1.1 APOL1 Mediated Kidney Disease Market Overview
1.1.1 APOL1 Mediated Kidney Disease Product Scope
1.1.2 APOL1 Mediated Kidney Disease Market Status and Outlook
1.2 Global APOL1 Mediated Kidney Disease Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global APOL1 Mediated Kidney Disease Market Size by Region (2018-2029)
1.4 Global APOL1 Mediated Kidney Disease Historic Market Size by Region (2018-2023)
1.5 Global APOL1 Mediated Kidney Disease Market Size Forecast by Region (2024-2029)
1.6 Key Regions, APOL1 Mediated Kidney Disease Market Size (2018-2029)
1.6.1 North America APOL1 Mediated Kidney Disease Market Size (2018-2029)
1.6.2 Europe APOL1 Mediated Kidney Disease Market Size (2018-2029)
1.6.3 Asia-Pacific APOL1 Mediated Kidney Disease Market Size (2018-2029)
1.6.4 Latin America APOL1 Mediated Kidney Disease Market Size (2018-2029)
1.6.5 Middle East & Africa APOL1 Mediated Kidney Disease Market Size (2018-2029)
2 APOL1 Mediated Kidney Disease Market by Type
2.1 Introduction
2.1.1 Small Molecule
2.1.2 Gene Modification
2.1.3 Nucleic Acid Therapies
2.1.4 Others
2.2 Global APOL1 Mediated Kidney Disease Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global APOL1 Mediated Kidney Disease Historic Market Size by Type (2018-2023)
2.2.2 Global APOL1 Mediated Kidney Disease Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America APOL1 Mediated Kidney Disease Revenue Breakdown by Type (2018-2029)
2.3.2 Europe APOL1 Mediated Kidney Disease Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific APOL1 Mediated Kidney Disease Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America APOL1 Mediated Kidney Disease Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa APOL1 Mediated Kidney Disease Revenue Breakdown by Type (2018-2029)
3 APOL1 Mediated Kidney Disease Market Overview by Application
3.1 Introduction
3.1.1 Chronic Kidney Disease
3.1.2 End Stage Kidney Disease
3.2 Global APOL1 Mediated Kidney Disease Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global APOL1 Mediated Kidney Disease Historic Market Size by Application (2018-2023)
3.2.2 Global APOL1 Mediated Kidney Disease Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America APOL1 Mediated Kidney Disease Revenue Breakdown by Application (2018-2029)
3.3.2 Europe APOL1 Mediated Kidney Disease Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific APOL1 Mediated Kidney Disease Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America APOL1 Mediated Kidney Disease Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa APOL1 Mediated Kidney Disease Revenue Breakdown by Application (2018-2029)
4 APOL1 Mediated Kidney Disease Competition Analysis by Players
4.1 Global APOL1 Mediated Kidney Disease Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in APOL1 Mediated Kidney Disease as of 2022)
4.3 Date of Key Players Enter into APOL1 Mediated Kidney Disease Market
4.4 Global Top Players APOL1 Mediated Kidney Disease Headquarters and Area Served
4.5 Key Players APOL1 Mediated Kidney Disease Product Solution and Service
4.6 Competitive Status
4.6.1 APOL1 Mediated Kidney Disease Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Vertex Pharmaceuticals
5.1.1 Vertex Pharmaceuticals Profile
5.1.2 Vertex Pharmaceuticals Main Business
5.1.3 Vertex Pharmaceuticals APOL1 Mediated Kidney Disease Products, Services and Solutions
5.1.4 Vertex Pharmaceuticals APOL1 Mediated Kidney Disease Revenue (US$ Million) & (2018-2023)
5.1.5 Vertex Pharmaceuticals Recent Developments
5.2 Ionis Pharmaceuticals
5.2.1 Ionis Pharmaceuticals Profile
5.2.2 Ionis Pharmaceuticals Main Business
5.2.3 Ionis Pharmaceuticals APOL1 Mediated Kidney Disease Products, Services and Solutions
5.2.4 Ionis Pharmaceuticals APOL1 Mediated Kidney Disease Revenue (US$ Million) & (2018-2023)
5.2.5 Ionis Pharmaceuticals Recent Developments
5.3 Travere Therapeutics
5.3.1 Travere Therapeutics Profile
5.3.2 Travere Therapeutics Main Business
5.3.3 Travere Therapeutics APOL1 Mediated Kidney Disease Products, Services and Solutions
5.3.4 Travere Therapeutics APOL1 Mediated Kidney Disease Revenue (US$ Million) & (2018-2023)
5.3.5 ChemoCentryx Recent Developments
5.4 ChemoCentryx
5.4.1 ChemoCentryx Profile
5.4.2 ChemoCentryx Main Business
5.4.3 ChemoCentryx APOL1 Mediated Kidney Disease Products, Services and Solutions
5.4.4 ChemoCentryx APOL1 Mediated Kidney Disease Revenue (US$ Million) & (2018-2023)
5.4.5 ChemoCentryx Recent Developments
5.5 ZyVersa Therapeutics
5.5.1 ZyVersa Therapeutics Profile
5.5.2 ZyVersa Therapeutics Main Business
5.5.3 ZyVersa Therapeutics APOL1 Mediated Kidney Disease Products, Services and Solutions
5.5.4 ZyVersa Therapeutics APOL1 Mediated Kidney Disease Revenue (US$ Million) & (2018-2023)
5.5.5 ZyVersa Therapeutics Recent Developments
5.6 GlaxoSmithKline
5.6.1 GlaxoSmithKline Profile
5.6.2 GlaxoSmithKline Main Business
5.6.3 GlaxoSmithKline APOL1 Mediated Kidney Disease Products, Services and Solutions
5.6.4 GlaxoSmithKline APOL1 Mediated Kidney Disease Revenue (US$ Million) & (2018-2023)
5.6.5 GlaxoSmithKline Recent Developments
5.7 Novartis
5.7.1 Novartis Profile
5.7.2 Novartis Main Business
5.7.3 Novartis APOL1 Mediated Kidney Disease Products, Services and Solutions
5.7.4 Novartis APOL1 Mediated Kidney Disease Revenue (US$ Million) & (2018-2023)
5.7.5 Novartis Recent Developments
5.8 Teva Pharmaceuticals
5.8.1 Teva Pharmaceuticals Profile
5.8.2 Teva Pharmaceuticals Main Business
5.8.3 Teva Pharmaceuticals APOL1 Mediated Kidney Disease Products, Services and Solutions
5.8.4 Teva Pharmaceuticals APOL1 Mediated Kidney Disease Revenue (US$ Million) & (2018-2023)
5.8.5 Teva Pharmaceuticals Recent Developments
6 North America
6.1 North America APOL1 Mediated Kidney Disease Market Size by Country (2018-2029)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe APOL1 Mediated Kidney Disease Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific APOL1 Mediated Kidney Disease Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America APOL1 Mediated Kidney Disease Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa APOL1 Mediated Kidney Disease Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 APOL1 Mediated Kidney Disease Market Dynamics
11.1 APOL1 Mediated Kidney Disease Industry Trends
11.2 APOL1 Mediated Kidney Disease Market Drivers
11.3 APOL1 Mediated Kidney Disease Market Challenges
11.4 APOL1 Mediated Kidney Disease Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List